Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average) (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Shares Outstanding (Weighted Average) data on file, last reported at $57.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $57.6 million, up 3.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.6 million (up 3.19% YoY), and the FY2025 annual result was $56.5 million, up 2.45% from the prior year.
• Shares Outstanding (Weighted Average) rose to $57.6 million in Q1 2026 per SUPN's latest filing, from $56.5 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $57.6 million in Q1 2026 and troughed at $53.3 million in Q1 2022.
• A 5-year average of $55.0 million and a median of $54.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) rose 0.76% in 2022, then advanced 3.19% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.7 million in 2022, then increased by 1.62% to $54.5 million in 2023, then advanced by 1.03% to $55.1 million in 2024, then rose by 2.45% to $56.5 million in 2025, then rose by 2.12% to $57.6 million in 2026.
• Business Quant data shows SUPN's Shares Outstanding (Weighted Average) at $57.6 million in Q1 2026, $56.5 million in Q4 2025, and $56.6 million in Q3 2025.